FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool
Executive Summary
FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system
You may also be interested in...
FDA’s Implementing Visionary: A Conversation With COO John Dyer
FDA's efforts to help usher in the bioinformatics era are personified by Deputy Commissioner for Operations John Dyer
FDA’s Implementing Visionary: A Conversation With COO John Dyer
FDA's efforts to help usher in the bioinformatics era are personified by Deputy Commissioner for Operations John Dyer
Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System
An active drug safety surveillance system is "doable," and would cost in the tens of millions of dollars, GlaxoSmithKline Chief Medical Officer Ronald Krall said during a recent Institute of Medicine symposium on the future of drug safety